HJC0152

Catalog No.S8561 Batch:S856101

Print

Technical Data

Formula

C15H13Cl2N3O4.HCl
Molecular Weight 406.65 CAS No. 1420290-99-8
Solubility (25°C)* In vitro DMSO 88 mg/mL (216.4 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description HJC0152 is a signal transducer and activator of transcription 3 (STAT3) inhibitor with remarkably improved aqueous solubility.
Targets
STAT3 [1]
In vitro HJC0152 inhibits STAT3 promoter activity in MDA-MB-231 cells in a dose-dependent manner. It has a comparable potency in downregulating STAT3 protein production and phosphorylation at the Tyr-705 site. HJC0152 induces cleaved caspase-3 and downregulated cyclin D1 in MDA-MB-231 cells, inhibits cell cycle progression and promotes apoptosis[1]. HJC0152 treatment efficiently suppresses HNSCC cell proliferation, arrests the cell cycle at the G0/G1 phase, induces apoptosis, and reduced cell invasion in both SCC25 and CAL27 cell lines. Moreover, HJC0152 inhibits nuclear translocation of phosphorylated STAT3 at Tyr705 and decreases VHL/β-catenin signaling activity via regulation of microRNA-21[2].
In vivo HJC0152 significantly suppresses MDA-MB-231 xenograft tumor growth in vivo (ip and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer. It has an improved oral bioavailability and an enhanced suppression of tumor growth in mice. HJC0152 does not show significant signs of toxicity at a dose of 75 mg/kg[1]. In SCC25-derived orthotopic mouse models, HJC0152 treatment significantly abrogates STAT3/β-catenin expression in vivo, which leading to a global decrease of tumor growth and invasion[2].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    MDA-MB-231 breast cancer cells

  • Concentrations

    1, 5, and 10 μM

  • Incubation Time

    24 h

  • Method

    The cells are treated with different doses of compound 11 for 24 h, and levels of total STAT3 and phosphorylated STAT3 at Tyr-705 are then examined by Western blot.
Animal Study:

[1]
  • Animal Models

    MDA-MB-231 xenograft model (nude mice)

  • Dosages

    2.5 and 7.5 mg/kg

  • Administration

    i.p.

Selleck's HJC0152 has been cited by 8 publications

Early Infiltration of Innate Immune Cells to the Liver Depletes HNF4α and Promotes Extrahepatic Carcinogenesis [ Cancer Discov, 2023, 13(7):1616-1635] PubMed: 36972357
High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway [ Cancer Commun (Lond), 2023, 43(5):562-581] PubMed: 37031362
Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer [ Cell Death Discov, 2023, 9(1):355] PubMed: 37752122
Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer [ Cell Death Discov, 2023, 9(1):355] PubMed: 37752122
Human α-Defensin 51-9 and Human β-Defensin 2 Improve Metabolic Parameters and Gut Barrier Function in Mice Fed a Western-Style Diet [ Int J Mol Sci, 2023, 24(18)13878] PubMed: 37762180
Human α-Defensin 51-9 and Human β-Defensin 2 Improve Metabolic Parameters and Gut Barrier Function in Mice Fed a Western-Style Diet [ Int J Mol Sci, 2023, 24(18)13878] PubMed: 37762180
STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity [Pei J Cancer Lett, 2019, 10.1016/j.canlet.2019.02.029] PubMed: 30790684
hJC0152, a novel sTaT3 inhibitor with promising anti-tumor effect in gastric cancer [Jiang X Cancer Manag Res, 2018, 10:6857-6867] PubMed: 30588091

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.